Late Breaking Abstract - Effectiveness and safety of mepolizumab in real-world clinical practice: the REALITI-A study

被引：5
|
作者：
Harrison, Tim [1 ]
Canonica, G. Walter [2 ]
Gemzoe, Kim [3 ]
Maxwell, Aoife [4 ]
Yang, Shibing [5 ]
Joksaite, Sandra [6 ]
O'Reilly, Ronan [4 ]
Van Dyke, Melissa [7 ]
Albers, Frank C. [8 ]
Kwon, Namhee [9 ]
机构：
[1] Univ Nottingham, City Hosp Nottingham, Nottingham NIHR Biomed Res Ctr, Nottingham, England
[2] Humanitas Univ, Dept Biomed Sci, Milan, Italy
[3] GSK, Global Med, Real World Study Delivery Value Evidence & Outcom, Uxbridge, Middx, England
[4] GSK, Global Med, Real World Study Delivery Value Evidence & Outcom, Uxbridge, Middx, England
[5] GSK, Value Evidence & Outcomes, Collegeville, PA USA
[6] GSK, R&D Projects Clin Platforms & Sci, Clin Stat, Uxbridge, Middx, England
[7] GSK, Epidemiol, Upper Providence, PA USA
[8] GSK, Resp Med Franchise, Res Triangle Pk, NC USA
[9] GSK, Resp Med Franchise, GSK House, Brentford, England
来源：
EUROPEAN RESPIRATORY JOURNAL | 2019年 / 54卷
关键词：
Severe asthma; Exacerbation;
D O I：
10.1183/13993003.congress-2019.OA2104
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
OA2104
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Real-World Benefits of Mepolizumab in Patients With Overlapping Allergic and Eosinophilic Endophenotypes: Post Hoc Analysis of REALITI-A by Omalizumab Eligibility
    Lee, Jason
    Pollard, Stephen
    Liu, Mark
    Schleich, Florence
    Pelaia, Girolamo
    Almonacid, Carlos
    Heaney, Liam
    Chaudhuri, Rekha
    Alfonso-Cristancho, Rafael
    Jakes, Rupert
    Price, Robert
    Maxwell, Aoife
    Howarth, Peter
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB21 - AB21
  • [22] How Real-World Mepolizumab Users in the REALITI-A Study Relate to the Recruitment Criteria Applied in the Randomized, Placebo-Controlled Trials of Subcutaneous Mepolizumab in Severe Eosinophilic Asthma
    Ramos-Barbon, D.
    Bals, R.
    Crimi, N.
    Menzies, D.
    Pek, B.
    Pilette, C.
    Steven, G.
    Alfonso-Cristancho, R.
    Jakes, R.
    Maxwell, A. C.
    Price, R. G.
    Yang, S.
    Howarth, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [23] The impact of mepolizumab self-administration on real-world outcomes in patients with severe asthma: Post hoc analysis of REALITI-A at 2 years
    Canonica, G. W.
    Demetriou, L.
    Schleich, F.
    Pelaia, G.
    Bernstein, D.
    Lee, F. E. H.
    Price, R. G.
    Howarth, P.
    ALLERGY, 2023, 78 : 185 - 186
  • [24] Late Breaking Abstract- Mepolizumab treatment in children and adolescents with severe eosinophilic asthma (CASAM)-A real-world study:initial analysis
    Gupta, Latika
    Messa, Ines De Mir
    Valverde-Molina, Jose
    Murray, Clare
    Izquierdo, Ana Diez
    Canavate, Ana Martinez
    Pike, Katharine
    Gracia, Carolina Diaz
    Callejon, Alicia Callejon
    Nagakumar, Prasad
    Blazquez, Olga De La Serna
    Cook, James
    Valdesoiro, Laura
    Moron, Juan Navarro
    Gaboli, Mirella
    Corullon, Silvia Castillo
    De Atauri, Alvaro Gimeno Diaz
    Aguilera, Pilar Caro
    Blasco, Jaime Lozano
    Aliaga, Yolanda
    Neyra, Alejandro Lopez
    Turnbull, Andrew
    Elosegui, Paula Corcuera
    Nwokoro, Chinedu
    Gupta, Atul
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [25] Real-world outcomes of patients with severe asthma treated with mepolizumab by baseline inhaled corticosteroid dose: Post hoc analysis of realiti-a at 2 years
    Smith, A.
    Patel, M.
    Caruso, C.
    Pilette, C.
    Welte, T.
    Alfonso-Cristancho, R.
    Price, R. G.
    Howarth, P.
    ALLERGY, 2023, 78 : 50 - 51
  • [26] Mepolizumab Reduces Clinically Significant Exacerbations in Patients With Severe Asthma Prior to and During the COVID-19 Pandemic: Results From the Real-world REALITI-A Study
    Schleich, F.
    Lougheed, M.
    Matucci, A.
    Hermosa, J. Rodriguez
    Pfeffer, P.
    Verghis, R. M.
    Jakes, R. W.
    Alfonso-Cristancho, R.
    Liu, M. C.
    Welte, T.
    Bals, R.
    Howarth, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [27] REAL-WORLD OUTCOMES WITH MEPOLIZUMAB IN PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA ACCORDING TO SMOKING HISTORY AND COPD STATUS AT ENROLLMENT: REALITI-A POST HOC ANALYSIS
    Bagnasco, Diego
    Hill, David G.
    Welte, Tobias
    Chaudhuri, Rekha
    Price, Robert
    Howarth, Peter
    CHEST, 2023, 164 (04) : 75A - 76A
  • [28] Rivaroxaban real-world evidence: Validating safety and effectiveness in clinical practice
    Beyer-Westendorf, Jan
    Camm, A. John
    Coleman, Craig I.
    Tamayo, C. A. P. T. Sally
    THROMBOSIS AND HAEMOSTASIS, 2016, 116 : S13 - S23
  • [29] UK severe asthma patient outcomes in the real-world versus Italy and the USA: REALITI-A at 2 years
    Weir, J.
    Egan, B.
    Heaney, L.
    Menzies, D.
    Pfeffer, P.
    Howarth, P.
    Chaudhuri, R.
    THORAX, 2023, 78 (SUPPL_4) : A184 - A184
  • [30] Late Breaking Abstract - Real-World Characteristics of Patients Receiving Dupilumab in Routine Clinical Practice in a Multinational, Non-Interventional Study (ProVENT)
    Lommatzsch, Marek
    Korn, Stephanie
    Schmidt, Olaf
    Timmermann, Hartmut
    Watz, Henrik
    Radwan, Amr
    De Prado-Gomez, Lucia
    Atenhan, Anne
    Barbus, Sebastian
    Thakur, Mayank
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
12345